Abstract 270P
Background
The companion diagnostic for olaparib against prostate cancer, which aims to detect BRCA1 or BRCA2 gene (BRCA1/2) variants, was investigated in December 2020 in Japan. There have been no reports on germline BRCA1/2 variants in actual clinical practice. Here, we evaluate germline BRCA1/2 variants and their relationship to the clinical characteristics and outcomes in prostate cancer.
Methods
Between June 2021 and June 2023, 92 patients with prostate cancer were examined using germline BRCA1/2 testing. Further, the associations between pathogenic variants and clinical outcomes were assessed.
Results
Of the 92 patients referred from the Iwate prefecture in Japan for genetic testing, six patients (6.5%) carried germline pathogenic variants; BRCA2 was the most frequent (n=5, 5.4%), followed by BRCA1 (n=1, 1.1%). Among the six variants in BRCA2, p.Ala338Valfs*11 was identified for the first time. Patients with the BRCA1/2 variant exhibited poor outcomes for overall survival from castration-resistant prostate cancer (CRPC), first-line androgen receptor-axis-targeted therapy (ARAT) for CRPC, and taxane chemotherapy (hazard ratio [HR] 4.77, 95% CI: 1.00 to 22.6, P=0.049; HR=5.27, 95% CI: 1.77 to 15.7, P=0.0028; and HR=7.47, 95% CI: 1.49 to 37.4, P=0.014, respectively).
Conclusions
In this study, patients with prostate cancer possessing germline variants of BRCA1/2 genes exhibited poor clinical response to ARAT for CRPC and taxane chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract